A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT04947553 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

456

Enrollment

INDUSTRY

Sponsor class

Conditions

Agitation in Patients With Dementia of the Alzheimer's Type
Alzheimer Disease
Agitation, Psychomotor

Interventions

DRUG: AXS-05 (dextromethorphan-bupropion)
DRUG: Placebo

Sponsor

Axsome Therapeutics, Inc.